VANCOUVER, Canada I October 17, 2013 I biOasis Technologies Inc. (TSX VENTURE:BTI) is pleased to announce that preclinical data on its proprietary BT2111 program will be presented during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, MA from October 19-23, 2013.
biOasis’ presentation entitled “BT2111, a new anticancer agent composed of trastuzumab and Transcend a vector for brain delivery for the treatment of metastatic HER2+ breast cancer”, will be presented on Sunday October 20th, 2013. The presentation will be held in exhibit hall C-D at 12:30PM under Session Title: Therapeutic Agents: Biological.
For more information on the conference please visit www.aacr.org/targetsconference
ABOUT TRANSCEND & BT2111
biOasis’ Transcend is a proprietary platform of carrier proteins capable of transporting therapeutics and other agents across the blood-brain barrier. BT2111 is a hybrid drug candidate consisting of a biOasis’ Transcend delivery vector linked to trastuzumab, a humanized monoclonal antibody used clinically in the treatment of HER2+ breast cancer. It is reported that up to 30% of HER2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. Because of its ability to cross the blood-brain barrier, biOasis is developing BT2111 as a potential treatment for brain metastases of HER2+ breast cancer.
ABOUT BIOASIS
biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the Company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the TSX Venture Exchange under the symbol “BTI”. For more information about the Company please visit www.bioasis.ca.
SOURCE: biOasis Technologies
Post Views: 188
VANCOUVER, Canada I October 17, 2013 I biOasis Technologies Inc. (TSX VENTURE:BTI) is pleased to announce that preclinical data on its proprietary BT2111 program will be presented during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, MA from October 19-23, 2013.
biOasis’ presentation entitled “BT2111, a new anticancer agent composed of trastuzumab and Transcend a vector for brain delivery for the treatment of metastatic HER2+ breast cancer”, will be presented on Sunday October 20th, 2013. The presentation will be held in exhibit hall C-D at 12:30PM under Session Title: Therapeutic Agents: Biological.
For more information on the conference please visit www.aacr.org/targetsconference
ABOUT TRANSCEND & BT2111
biOasis’ Transcend is a proprietary platform of carrier proteins capable of transporting therapeutics and other agents across the blood-brain barrier. BT2111 is a hybrid drug candidate consisting of a biOasis’ Transcend delivery vector linked to trastuzumab, a humanized monoclonal antibody used clinically in the treatment of HER2+ breast cancer. It is reported that up to 30% of HER2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. Because of its ability to cross the blood-brain barrier, biOasis is developing BT2111 as a potential treatment for brain metastases of HER2+ breast cancer.
ABOUT BIOASIS
biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the Company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the TSX Venture Exchange under the symbol “BTI”. For more information about the Company please visit www.bioasis.ca.
SOURCE: biOasis Technologies
Post Views: 188
